Central Serous Chorioretinopathy - Pipeline Insight, 2024

This “Central Serous Chorioretinopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Serous Chorioretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Central Serous Chorioretinopathy Understanding

Central Serous Chorioretinopathy: Overview

Central serous Chorioretinopathy is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. Central serous Chorioretinopathy most often occurs in young and middle-aged adults. For unknown reasons, men develop this condition more commonly than women. Vision loss is usually temporary but sometimes can become chronic or recur. A complete dilated eye examination of both eyes to obtain the image of the retina. Retinal photographs may be taken to document the appearance of disease. Optical coherence tomography (OCT) is a retinal scan that is very helpful in diagnosing Central Serous Chorioretinopathy. Fluorescein angiography is a test in which a dye is injected into a patient's arm vein and pictures are taken of each eye to detect characteristic leakage of the dye beneath the patient's retina. Several therapies have been used to treat chronic CSC, including thermal laser treatments, oral medications, and eye injections. A “cold laser,” called photodynamic therapy, is also effective and often used to focally treat the source of fluid leakage under the retina in chronic CSC. Early detection of CSC is very helpful, and most eyes with CSC can be treated successfully to avoid permanent vision loss.

Central Serous Chorioretinopathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Serous Chorioretinopathy pipeline landscape is provided which includes the disease overview and Central Serous Chorioretinopathy treatment guidelines. The assessment part of the report embraces, in depth Central Serous Chorioretinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Serous Chorioretinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Central Serous Chorioretinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Central Serous Chorioretinopathy.

Central Serous Chorioretinopathy Emerging Drugs Chapters

This segment of the Central Serous Chorioretinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Central Serous Chorioretinopathy Emerging Drugs

Aflibercept: Bayer Aflibercept is a drug that is a placenta growth factor inhibitors and vascular endothelial growth factor A inhibitors. It is was originally developed by Regeneron Pharmaceuticals and later licensed to Bayer and Sanofi. It is currently in Phase II of clinicalstudy.

Central Serous Chorioretinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Central Serous Chorioretinopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Central Serous Chorioretinopathy

There are approx. 3+ key companies which are developing the therapies for Central Serous Chorioretinopathy. The companies which have their Central Serous Chorioretinopathy drug candidates in the most advanced stage, i.e. Phase II include, Bayer.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Central Serous Chorioretinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Central Serous Chorioretinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Serous Chorioretinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Serous Chorioretinopathy drugs.

Central Serous Chorioretinopathy Report Insights

• Central Serous Chorioretinopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Central Serous Chorioretinopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Central Serous Chorioretinopathy drugs?
• How many Central Serous Chorioretinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Serous Chorioretinopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Central Serous Chorioretinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Central Serous Chorioretinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.